The per share price values Santarus at $2.6 billion, a 39 percent premium over the company’s 30-day trading average.
The acquisition will help Salix solidify its lead in the gastrointestinal market, and the companies’ combined revenue would be approximately $1.3 billion.
More Articles on Gastroenterology:
72% of Adults Have Not Sought Physician Help for GI Pain
Physicians Endoscopy Receives Cost Management Performance Award
Dr. Glenn Madokoro Gives GI Patients Access to Information Technology
